## **Preface**

The Food and Drug Administration (FDA) is pleased to present its fiscal year 2004 financial report. The report's management discussion and analysis (MD&A) has been streamlined to meet the accelerated financial reporting requirements for Executive Branch's financial reports.

**Section I** – "Management Discussion and Analysis" (MD&A) is designed to provide a high level overview of the Agency's mission and how it accomplishes that mission. The MD&A is organized into four chapters containing the following:

- Agency Overview Chapter Provides mission, strategic goals, and organizational structure. Discusses assurance statements, reliability of performance data, accounting presentation requirements, and challenges and future trends affecting FDA's financial condition.
- Program Management Chapter Discusses FDA's strategic goals, select performance goals, and performance results.
- Operational Effectiveness Chapter Highlights FDA's progress implementing the President's Management Agenda.
- Fiscal Responsibility Chapter Reports on the results of the financial statement audit and analyses FDA's financial condition as displayed in the consolidated principal financial statements.

**Section II** – "Consolidated Principal Financial Statements" provides the principal financial statements and explanatory notes.

**Section III** – "Required Supplementary Information" contains unaudited financial statements that provide a level of detail regarding the status of budgetary resources, net costs by program and by type, deferred maintenance, and intragovernmental transactions in three categories (assets, liabilities, and revenues and expenses).

**Section IV** – "Required Supplementary Stewardship Information" reports on research and development expenses covered under stewardship reporting.

**Section V** – "Reports on the Audit of FDA's FY 2004 Financial Statements" contains the Office of Inspector General's Transmittal Letter; three auditors' reports on consolidated financial statements, internal controls over financial reporting, and compliance with laws and regulations; and the FDA response to the auditors' report.

Appendix – Defines a list of FDA acronyms used in the report.

## FDA FY 2004 Annual Financial Report

## Report Availability and Contact Information:

The FDA Annual Financial Report for FY 2004 is available on the Office of Financial Management Web Page at: <a href="www.fda.gov/oc/oms/ofm/accounting/ofmaccounting.htm">www.fda.gov/oc/oms/ofm/accounting/ofmaccounting.htm</a>. For questions regarding the Annual Financial Report, please contact:

Acting Chief, CFO Liaison Branch Division of Accounting 5600 Fishers Lane Rockville, MD 20857 301-827-4792